Filing Flows › Companies › 10x Genomics › Report card
10x Genomics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate5 of 5 reports beat the EPS estimate
10x Genomics (TXG) beat the analysts' EPS estimate in 5 of its last 5 reports (100%), by +143.3% on average.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue guided | Revenue reported |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | −$0.02 | $0.03 | n/m | — | $151M |
| Q2 2026 | Aug 7, 2026 | −$0.02 | $0.03 | n/m | — | $151M |
| Q1 2026 | May 7, 2026 | −$0.06 | $0.07 | +219.2% | — | $151M |
| Q4 2025 | Feb 12, 2026 | −$0.04 | $0.07 | n/m | $154M–$158M | $166M (above) |
| Q3 2025 | Nov 6, 2025 | −$0.07 | −$0.02 | +67.4% | $140M–$144M | $149M (above) |
Estimates and reported EPS are the Street's adjusted figures. Revenue guided is the last range the company gave before the report. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
How credible is its guidance?
Revenue: of 5 guided periods, 5 came in beyond the top end of the range, 0 within and 0 short of it; 5 of 5 on the better side of the midpoint, on average +8.1% against the midpoint (+ is better). Guidance has been conservative: results beat the range itself. On that record the odds the next lands on the better side of the midpoint are about 86%.
Position in the range: 0 is the worse end, 1 the better end (for costs and tax rates, lower). Odds are the record plus one each way (Laplace), not a forecast.
The next report: what to expect → 10x Genomics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.